<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114279">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01870167</url>
  </required_header>
  <id_info>
    <org_study_id>Pediatric- PEG</org_study_id>
    <nct_id>NCT01870167</nct_id>
  </id_info>
  <brief_title>Antibiotic Prophylaxis for PEG in Children</brief_title>
  <official_title>Antibiotic Prophylaxis for Percutaneous Endoscopic Gastrostomy (PEG) in Children: a Randomised Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Policlinico Umberto I</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Policlinico Umberto I</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate if a single i.v. dose of co-amoxiclav before PEG can
      reduce the incidence of peristomal wound infection in the paediatric population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Percutaneous  Endoscopic  Gastrostomy (PEG) is a common endoscopic procedure, performed to
      avoid malnutrition in various pathological conditions.

      Gastrostomy tube placement is associated with intra and postoperative complications both in
      the adult and in the paediatric population.

      Local infection is the most common complication following PEG.

      Antibiotic prophylaxis is a well-established strategy to reduce peristomal wound infection
      rate in adult population.

      The aim of this study is to evaluate if a single i.v. dose of co-amoxiclav before PEG can
      reduce the incidence of peristomal wound infection in the paediatric population.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>24 hours after PEG insertion</time_frame>
    <safety_issue>No</safety_issue>
    <description>24 hours after PEG insertion PEG site will be examined for erythema, induration and exudate and scored using the peristomal sepsis scoring system.
PEG site infection will be defined as presence of pus or a score of 8 or more, with or without microbiological evidence of bacterial or fungal infection from PEG site swabs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>14 days after PEG insertion</time_frame>
    <safety_issue>No</safety_issue>
    <description>14 days after PEG insertion PEG site will be examined for erythema, induration and exudate and scored using the peristomal sepsis scoring system.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>24 hours after PEG insertion</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary outcomes are occurrence of systemic infection, defined as persistent fever (temperature &gt;38.0 °C for &gt;24 h) or clinical, laboratory and microbiological evidence of invasive sepsis and objective signs of infection, including a positive bacterial or fungal culture, high levels of highly sensitive C reactive protein, and a high white blood cell count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>14 days after PEG insertion</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary outcomes are occurrence of systemic infection, defined as persistent fever (temperature &gt;38.0 °C for &gt;24 h) or clinical, laboratory and microbiological evidence of invasive sepsis and objective signs of infection, including a positive bacterial or fungal culture, high levels of highly sensitive C reactive protein, and a high white blood cell count.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>co-amoxiclav</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>co-amoxiclav is a combination antibiotic consisting of amoxicillin trihydrate, a β-lactam antibiotic, and potassium clavulanate, a β-lactamase inhibitor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>co-amoxiclav</intervention_name>
    <description>a single iv dose of co-amoxiclav (50/mg/Kg) at the time of PEG insertion.</description>
    <arm_group_label>co-amoxiclav</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All pediatric patients (0-18 years) who will refer for PEG placement to the endoscopy
             unit

        Exclusion Criteria:

          -  Controindications for PEG

          -  Ongoing antibiotic treatment

          -  Antibiotic use within the past 4 days

          -  Illness too severe to allow the patient to participate

          -  Allergy to penicillin
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Pediatrics</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Department of Pediatrics</last_name>
      <phone>0649979326</phone>
      <email>giovanni.dinardo@uniroma1.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>June 4, 2013</lastchanged_date>
  <firstreceived_date>May 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Policlinico Umberto I</investigator_affiliation>
    <investigator_full_name>Giovanni Di Nardo</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>PEG</keyword>
  <keyword>Percutaneous  Endoscopic  Gastrostomy</keyword>
  <keyword>antibiotic prophylaxis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
